Literature DB >> 20559040

Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa.

Cheryl Cohen1, Elvira Singh, Henry M Wu, Stacey Martin, Linda de Gouveia, Keith P Klugman, Susan Meiring, Nelesh Govender, Anne von Gottberg.   

Abstract

OBJECTIVES: We aimed to compare the incidence of meningococcal disease amongst HIV-infected and uninfected individuals and to evaluate whether HIV is a risk factor for mortality and bacteremia amongst patients with meningococcal disease.
DESIGN: Cohort surveillance study.
METHODS: We conducted laboratory-based surveillance for meningococcal disease in Gauteng Province, South Africa. HIV status and outcome data were obtained at sentinel sites. Incidence in HIV-infected and uninfected persons was calculated assuming a similar age-specific HIV prevalence in tested and untested individuals. Risk factors for death and bacteremia (as compared with meningitis) were evaluated using multivariable logistic regression.
RESULTS: From 2003 to 2007, 1336 meningococcal cases were reported. Of 504 patients at sentinel sites with known outcome, 308 (61%) had HIV serostatus data. HIV prevalence amongst cases of meningococcal disease was higher than the population HIV prevalence in all age groups. The incidence of meningococcal disease in HIV-infected individuals was elevated in all age groups with an age-adjusted relative risk of 11.3 [95% confidence interval (CI) 8.9-14.3, P < 0.001]. The case-fatality ratio (CFR) was 20% (27/138) amongst HIV-infected and 11% (18/170) amongst HIV-uninfected individuals [odds ratio (OR) 2.1, 95% CI 1.1-3.9]. On multivariable analysis, CFR was greater amongst patients with bacteremia (35%, 29/82) compared with meningitis (7%, 16/226) (OR 7.8, 95% CI 3.4-17.7). HIV infection was associated with increased odds of bacteremia (OR 2.7, 95% CI 1.5-5.0).
CONCLUSION: HIV-infected individuals may be at increased risk of meningococcal disease. The increased CFR in HIV-infected patients may be explained by their increased odds of bacteremia compared to meningitis.

Entities:  

Mesh:

Year:  2010        PMID: 20559040     DOI: 10.1097/QAD.0b013e32833a2520

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  21 in total

1.  Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.

Authors:  Ana Cristina C Frota; Lucimar G Milagres; Lee H Harrison; Bianca Ferreira; Daniela Menna Barreto; Gisele S Pereira; Aline C Cruz; Wania Pereira-Manfro; Ricardo Hugo de Oliveira; Thalita F Abreu; Cristina B Hofer
Journal:  Pediatr Infect Dis J       Date:  2015-05       Impact factor: 2.129

Review 2.  Invasive meningococcal disease in the 21st century—an update for the clinician.

Authors:  Rachel Dwilow; Sergio Fanella
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

3.  Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.

Authors:  Jorge Lujan-Zilbermann; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Mark J Abzug; Barb Heckman; Adam Manzella; Bill Kabat; Patrick Jean-Philippe; Sharon Nachman; George K Siberry
Journal:  J Pediatr       Date:  2012-05-22       Impact factor: 4.406

4.  Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Authors:  George K Siberry; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Patrick Jean-Philippe; Ram Yogev; Barbara E Heckman; Adam Manzella; Jhoanna Roa; Sharon Nachman; Jorge Lujan-Zilbermann
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

5.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

6.  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Authors:  Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil
Journal:  MMWR Recomm Rep       Date:  2020-09-25

Review 7.  Population-based epidemiology and microbiology of community-onset bloodstream infections.

Authors:  Kevin B Laupland; Deirdre L Church
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 8.  Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.

Authors:  Mustapha M Mustapha; Lee H Harrison
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

9.  Invasive meningococcal disease in men who have sex with men.

Authors:  Matthew S Simon; Don Weiss; Roy M Gulick
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

Review 10.  Clinical and Microbiological Features of Salmonella Meningitis in a South African Population, 2003-2013.

Authors:  Karen H Keddy; Arvinda Sooka; Alfred Musekiwa; Anthony M Smith; Husna Ismail; Nomsa P Tau; Penny Crowther-Gibson; Frederick J Angulo; Keith P Klugman
Journal:  Clin Infect Dis       Date:  2015-11-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.